Yet genotype-based risks for GPVs that deviate from the “typical” cancer risks attributed to a specific gene, such as the CHEK2 I157T GPV, cannot be used in these risk models, which poses challenges to translation and incorporation of this information in clinic to generate risk estimates for patients. The gene discussed is CHEK2; the disease is cancer.